Competitor Analysis: Targeted Therapy of Hepatitis C

Date: August 22, 2011
Pages: 91
Price:
US$ 826.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C90E2CCCB38EN
Leaflet:

Download PDF Leaflet

Competitor Analysis: Targeted Therapy of Hepatitis C
Product description

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-? administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and additional comments with a hyperlink leading to the source of information.
Index
  • HCV Protease Inhibitors
  • HCV RNA Polymerase Inhibitors
  • Cyclophilin Inhibitors
  • HCV NS5A Protein Inhibitors
  • HCV NS4B-RNA Binding Inhibitors
  • Therapeutic & Preventative HCV Vaccines
  • Therapeutic HCV Antibodies
  • HCV Viral Entry Inhibitors
  • HCV Replication Inhibitors
  • Novel Mechanism of Action HCV Virus & Host Cell Targets
  • TLR Agonists
  • Various
  • Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
  • About La Merie
Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
  • Abbott
  • Achillion Pharmaceuticals
  • Alios Biopharma
  • Altor Biosciences
  • Anadys Pharmaceuticals
  • Astex Therapeutics
  • Avila Therapeutics
  • Bionor Immuno
  • Biotica Technology
  • Biotron
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • C-Pharma
  • Can-Fite BioPharma
  • Chimerix
  • ChronTech Pharma
  • Compass Biotechnologies
  • Conatus Pharmaceuticals
  • CureTech
  • Cytheris
  • Debiopharm
  • Dynavax Technologies
  • Eiger Pharmaceuticals
  • Enanta Pharmaceuticals
  • Epiphany Biosciences
  • Epixis
  • Genmab
  • GenPhar
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Heat Biologics
  • Idenix Pharmaceuticals
  • Idera Pharmaceuticals
  • Inhibitex
  • Inovio
  • Intellektualniy Dialog
  • Intercell
  • iTherX Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson (J&J)
  • Medivir
  • Massachusetts Biologic Laboratories (MBL)
  • Merck & Co
  • Mitsubishi Tanabe Pharma
  • Morningside Asia Venture
  • Novartis
  • Okairos
  • Ono Pharmaceutical
  • Paladin Biosciences
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmasset
  • PTC Therapeutics
  • Presidio Pharmaceuticals
  • Progenics Pharmaceuticals
  • Regulus Therapeutics
  • Replicor
  • Roche
  • Rosetta Genomics
  • Samaritan Pharmaceuticals
  • Santaris Pharma
  • SCYNEXIS
  • Tacere Therapeutics
  • TaiGen Biotechnology
  • Teva Pharmaceutical Industries
  • Theravance
  • Transgene
  • Tripep
  • Vertex Pharmaceuticals
  • Viriome
  • Virionics
  • ViroBay
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top


Ask Your Question

Competitor Analysis: Targeted Therapy of Hepatitis C
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: